Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Moderna, inc. save search
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.59%
H: 2.09%
C: -1.74%
rna-3927 mrna therapy
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.18%
C: -3.94%
commercial
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Published: 2023-12-11 (Crawled : 14:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 1.06%
H: 0.59%
C: -0.46%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.47%
H: 3.28%
C: 2.58%
rna-4157 keytruda lung merck cancer cell treatment study
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.21%
H: 2.08%
C: 1.99%
work year
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
Published: 2023-10-31 (Crawled : 14:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -1.57%
H: 4.44%
C: 4.18%
pre-clinical mrna collaboration platform
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.42%
C: -0.94%
covid-19 fda vaccine approval
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Published: 2023-07-26 (Crawled : 11:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -0.68%
H: 1.13%
C: 0.32%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.07%
C: -1.0%
rna-4157 keytruda melanoma merck treatment study
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
Published: 2023-07-05 (Crawled : 13:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.95%
H: 4.96%
C: 0.53%
mrna-1345 respiratory global virus
MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
Published: 2023-06-29 (Crawled : 23:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.41%
H: 0.39%
C: -0.32%
covid-19 vaccine health canada submission
Global Cancer Vaccine Industry Worth $13.4 Billion by 2030: Use of Nanosensors in Diagnosing Cancer Expected to Create Ample Opportunities for Key Players
Published: 2023-06-27 (Crawled : 10:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.03%
H: 0.37%
C: 0.18%
DVAX | $11.35 -0.7% -0.7% 2.2M
|
Health Technology
|
| O: 0.08%
H: 1.31%
C: 0.77%
vaccine expected cancer global
Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
Published: 2023-06-22 (Crawled : 21:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.26%
C: -0.43%
covid-19 fda vaccine authorization
Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement
Published: 2023-06-07 (Crawled : 13:00) - prnewswire.com
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.24%
H: 0.39%
C: -0.77%
covid-19 patent vaccine
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Published: 2023-05-19 (Crawled : 12:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.05%
rna-3927 mrna meeting therapy
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
Published: 2023-05-18 (Crawled : 13:20) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: 0.0%
H: 0.65%
C: -4.35%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -1.87%
H: 2.72%
C: -1.63%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: -2.82%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 0.28%
H: 0.07%
C: -0.47%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: -0.15%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 8.57%
H: 1.97%
C: -1.32%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.3%
H: 2.6%
C: 2.36%
MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES
Published: 2023-05-04 (Crawled : 18:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 2.91%
H: 3.2%
C: 0.3%
pharma mrna agreement
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
Published: 2023-05-03 (Crawled : 00:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.67%
H: 1.81%
C: -0.29%
rna-3927 mrna meeting therapy
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
Published: 2023-04-20 (Crawled : 12:00) - biospace.com/
IBM | $181.47 -0.89% -0.53% 2.9M
|
Technology Services
|
| O: 3.03%
H: 0.64%
C: -2.91%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.99%
H: 2.14%
C: -0.18%
quantum mrna
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Published: 2023-02-16 (Crawled : 17:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: 1.62%
H: 4.61%
C: 2.66%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -1.29%
H: 0.0%
C: -5.9%
CRL | $227.55 -1.1% 0.0% 710K
|
Commercial Services
|
| O: -1.98%
H: 4.31%
C: 3.13%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -1.75%
H: 3.17%
C: -0.2%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -2.37%
H: 1.81%
C: -0.44%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -2.57%
H: 5.44%
C: -1.98%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 5.58%
H: 2.0%
C: -4.13%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -1.75%
H: 2.08%
C: -0.61%
medical agreement
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -1.12%
H: 0.19%
C: -3.4%
rna-1345 fda designation candidate vaccine respiratory virus granted therapy
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
Published: 2022-12-16 (Crawled : 18:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.42%
H: 1.69%
C: -6.34%
covid-19 children ema
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.